ライフサイエンスコーパス: growth inhibitor

1 cule, an angiogenic factor, and a tumor cell growth inhibitor.

2 e accelerated, consistent with its role as a growth inhibitor.

3 and by SMCs themselves, acts as a potent SMC growth inhibitor.

4 ison, ICI 182,780 is the more effective cell growth inhibitor.

5 poietic cells is abrogation of response to a growth inhibitor.

6 that transform it into a potent beta-hematin growth inhibitor.

7 ereas palmitoleate (16:1Delta9) was a potent growth inhibitor.

8 tress-responsive tumor suppressor and potent growth inhibitor.

9 ave a role in synthesis of the lateral shoot growth inhibitor.

10 the absence of mitogen or in the presence of growth inhibitors.

11 sent a novel class of angiogenesis and tumor-growth inhibitors.

12 ction of multiple intracellular and secreted growth inhibitors.

13 -beta, antiestrogens, but not estrogens, are growth inhibitors.

14 m has yielded a number of potent cancer cell growth inhibitors.

15 MCs) by the expression of cell migration and growth inhibitors.

16 e growth arrest in response to extracellular growth inhibitors.

17 urally to OSM and LIF, were not active as EC growth inhibitors.

18 sponding tautomer(s) produces native crystal growth inhibitors.

19 rarely achieved by more conventional crystal growth inhibitors.

20 active target for Mycobacterium tuberculosis growth inhibitors.

21 of anchorage-independent breast cancer cell growth inhibitors.

22 n primary cultured neurons exposed to axonal growth inhibitors.

23 cystine stones by rational design of crystal growth inhibitors.

24 e by molecules such as the myelin-associated growth inhibitors.

25 S), in particular regarding the role of axon-growth inhibitors.

26 0001 microg/mL) murine and human cancer cell growth inhibitors.

27 The most potent cell growth inhibitor 2 (GI(50) = 0.495 muMm HCT-116 cells) s

28 A BCG growth inhibitor, 2-thiophenecarboxylic acid hydrazide (

29 identified as a potential target of the cell growth inhibitor 5-fluorouracil.

30 s and their expression alteration by diverse growth inhibitors across cell types, we prioritize 30 hi

31 RpL17 acts as a vascular smooth muscle cell growth inhibitor (akin to a tumor suppressor) and repres

32 y identified and characterized a novel tumor growth inhibitor and a fatty acid-binding protein in hum

33 ne (1) has been converted to the cancer cell growth inhibitor and antibiotic designated hystatin 2 (8

34 ing growth factor-beta (TGFbeta) is a potent growth inhibitor and inducer of apoptosis in B lymphocyt

35 4HPR concentrations at which it is a potent growth inhibitor and inducer of apoptosis.

36 ng growth factor beta (TGF-beta) is a potent growth inhibitor and inducer of cell death in B-lymphocy

37 ls mediolateral outgrowth by repression of a growth inhibitor and promotion of cell division at primo

38 t sequence homology to mouse mammary-derived growth inhibitor and thus was named mammary-derived grow

39 ng effector to antagonist/from antagonist to growth inhibitor and vice versa.

40 and will enable the design of more efficient growth inhibitors and facilitate an understanding of the

41 lyses attributed the regeneration failure to growth inhibitors and lack of intrinsic growth potential

42 Following SCI, axon growth inhibitors and other inflammatory responses preve

43 We propose a model in which a balance of growth inhibitors and promoters determines tissue growth

44 ence, despite the activation of a cascade of growth inhibitors and senescence markers, and are permis

45 ge-like cells secrete a variety of potent EC growth inhibitors and that one of these, OSM, is among t

46 Consequently, growth inhibitors and their common receptor have been id

47 ay be extended for the identification of new growth inhibitors and their targets across bacterial spe

48 sulfatide as a novel myelin-associated axon growth inhibitor, and provide evidence that sulfatide in

49 strate that mCLCA5 is a detachment-sensitive growth inhibitor, and suggest a mechanism whereby these

50 romote axon growth, remove myelin-associated growth inhibitors, and guide regenerating axons to their

51 rotrusions but may be achieved with multiple growth inhibitors, and that other types of signals can r

52 We hypothesized that production of the growth inhibitor angiostatin increases during decreased

53 s of alpha-syn fibril growth and to identify growth inhibitors as a potential therapeutic approach in

54 e result of direct suppression of a few cell growth inhibitors at the early stage of miRNA overexpres

55 hydrolysate) and in the presence of several growth inhibitors (beta-glucoside, D-fucose, valine and

56 g growth factor beta-1 (TGFbeta-1) acts as a growth inhibitor, but in malignant cells it may act as a

57 in, often down-regulated in PCa, is a potent growth inhibitor by inducing G(0)/G(1) cell cycle arrest

58 Here, we show that a synthetic growth inhibitor called pyrabactin functions as a select

59 However, mutations in genes that encode growth inhibitors can trigger the onset of tumorigenesis

60 We found that the axon growth inhibitor chondroitin sulfate proteoglycan (CSPG)

61 We analyzed the effect of three putative growth inhibitors--chondroitin sulfate, serum albumin, a

62 nts led to synthesis of a potent cancer cell growth inhibitor designated phenstatin (3b).

63 led to the discovery of a potent cancer cell growth inhibitor designated phenstatin (5a).

64 The potency of these compounds as yeast growth inhibitors directly correlates with their lipophi

65 ded a practical synthesis of the cancer cell growth inhibitor dolastatin 18 (2, Dhex-(S)-Leu-(R)-N-Me

66 sentiality, and the identification of potent growth inhibitors either in vitro or in an infection mod

67 Here, we identified five growth inhibitors encoded by T7 bacteriophage.

68 sults reveal hCLCA2 as a novel p53-inducible growth inhibitor, explain how its down-regulation confer

69 growth factor beta1 (TGF-beta1) is a potent growth inhibitor for a variety of cultured cells.

70 log, was previously indicated to be a potent growth inhibitor for Hep 3B hepatoma cells in vitro.

71 In the skin, TGFB signaling is a growth inhibitor for keratinocytes and a profibrotic fac

72 ANUP is a strong growth inhibitor for KS cell lines, but has little or no

73 tions in the activation of TGFbeta, a potent growth inhibitor for most cell types, the degradation of

74 Although ADP has been reported to be a growth inhibitor for vascular EC, here we describe its g

75 itors, alvocidib and dinaciclib as potent HB growth inhibitors for the high-risk C2 molecular subtype

76 ces of the genes potentially targeted by the growth inhibitors from our compound screens.

77 After CNS injuries, axon growth inhibitors from the myelin and the scar tissue at

78 A growth inhibitor, galectin-1, was downregulated in the h

79 Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its e

80 increase or decrease expression of the bone growth inhibitor gene Stanniocalcin2a in developing spin

81 Notably, we found a previously unidentified growth inhibitor, gene product (Gp) 0.6, that interacts

82 Here, we describe a bacterial growth inhibitor, gene product T5.015, encoded by the T5

83 of (S)-(+)-tylophorine, a potent cancer cell growth inhibitor, has been accomplished in eight steps f

84 ctor beta1 (TGFbeta1), a potent keratinocyte growth inhibitor, has been shown to be overexpressed in

85 Compounds 3-6 were potent growth inhibitors (IC(50) 4.7-334 nM) of human tumor cel

86 lected tropical diseases for Cryptosporidium growth inhibitors identifies the 6-carboxamide benzoxabo

87 Supporting its role as a primary growth inhibitor, IGFBP-3 production has been shown to b

88 rosis factor-mediated apoptosis, is a potent growth inhibitor in human prostate cancer (PCa).

89 findings couple the activity of an important growth inhibitor in liver to the induction of autophagy

90 etinol (AR), has long been known to act as a growth inhibitor in lymphocytes, whereas 14-hydroxy-4,14

91 hibitor of Src (as measured in vitro), and a growth inhibitor in NIH 3T3 cells.

92 Nogo-A is an important axonal growth inhibitor in the adult and developing CNS.

93 idance molecule A (RGMa) is a potent neurite growth inhibitor in the central nervous system, exerting

94 To prove that RpL17 acted as a growth inhibitor in vivo, we used pluronic gel delivery

95 U145, consistent with a role for beta1C as a growth inhibitor in vivo.

96 nique antineoplastic activity and are potent growth inhibitors in a variety of cultured cells.

97 available fluoro monosaccharides as putative growth inhibitors in Arabidopsis thaliana revealed that

98 ught to mediate the action of several axonal growth inhibitors in the adult brain and spinal cord.

99 Importantly, neuron-intrinsic growth inhibitors in the adult nervous system, including

100 se, but also to signals elicited by specific growth inhibitors in the context of a particular biologi

101 iral nucleoside treatment and not induced by growth inhibitors, in contrast to fungal dsRNA viruses.

102 DX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding prot

103 We show that a single growth inhibitor is insufficient for the formation of mu

104 On the {001} face, growth inhibitors like biuret compete with urea for the

105 Miniature species consistently overexpress growth inhibitors like CDKN1B and ING2, associated with

106 er effects (NOEs), we define portions of the growth inhibitor likely to be accessible on the cell sur

107 f the crystal habit and polymorph by crystal growth inhibitors may not affect crystal aggregation or

108 Mammary derived growth inhibitor (MDGI) is a member of the family of cyt

109 port inhibitor of complex I (MET-I) and mite growth inhibitor (MGI) acaricides on multiple T. urticae

110 1 and survivin and upregulation of the tumor growth inhibitor molecule p38 MAPK.

111 For growth inhibitors, mRNA expression for transforming grow

112 The target of such bacterial-growth inhibitors must be identified, and one way to ach

113 The myelin-derived neurite growth inhibitor Nogo has been proposed to play a major

114 binding two receptors for myelin-associated growth inhibitors, Nogo receptors 1 and 3.

115 that the biosynthetic pathway for this plant growth inhibitor occurs in root hair cells, involving a

116 ctor beta (TGF-beta) is known to be a potent growth inhibitor of breast cancer cells (BCCs), the sign

117 lls that survived chemotherapy but also as a growth inhibitor of cells that survived hypoxia.

118 However, trastuzumab is a better growth inhibitor of ECC-1TAM tumors where there is dimin

119 TGF-beta is a potent growth inhibitor of epithelial cells.

120 inst Cdc25B(2) in vitro and less potent as a growth inhibitor of human breast cancer cells.

121 more, we have found activin A to be a potent growth inhibitor of MCF- 7 cells (at 2 ng/ml), where it

122 hoxyethylamino-numonafide (MEAN) is a potent growth inhibitor of murine xenografts of 2 human HCC cel

123 This action of Slit2 as a growth inhibitor of retinal axons and the expression pat

124 The glycosaminoglycan heparin is a growth inhibitor of SMCs in vitro and in vivo.

125 pal mechanisms that disulfiram operates as a growth inhibitor of Staphylococcus aureus using differen

126 1 and 3 except that 2 was a much more potent growth inhibitor of the two vulvar cell lines, which is

127 abino-hexopyranoside 2 was also an effective growth inhibitor of two drug-resistant leukemic cell lin

128 amino-1,4-naphthoquinone (PD-42), are potent growth inhibitors of 13 different human cancer cell line

129 (RA) have been demonstrated to be effective growth inhibitors of a number of human cancer cell lines

130 , such as the small molecule JQ1, are potent growth inhibitors of many cancers and hold promise for c

131 icular, semisynthetic analogue 5, are strong growth inhibitors of Mycobacterium tuberculosis H37Rv.

132 icrowave heating and evaluated as noteworthy growth inhibitors of Plasmodium falciparum (3D7 and W2)

133 A screen of fatty acids as growth inhibitors of Staphylococcus aureus revealed stru

134 tally confirm, three human-targeted drugs as growth inhibitors of Staphylococcus aureus.

135 evels of combined potency and selectivity as growth inhibitors of T. gondii and as inhibitors of the

136 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite th

137 pid A biosynthesis is required for bacterial growth, inhibitors of LpxC have potential utility as ant

138 on-defective cancers depend on Pol theta for growth, inhibitors of Pol theta may be useful in treatin

139 In the adult mammalian CNS, the growth inhibitors oligodendrocyte-myelin glycoprotein (O

140 d has been used to quantitate the effects of growth inhibitors on cells in 96-well cultures.

141 ctions governing site-specific adsorption of growth inhibitors on crystal surfaces can be tailored in

142 GF-beta) serves as either an epithelial cell growth inhibitor or a tumor promoter, depending on the c

143 l myelinated CNS environment contains potent growth inhibitors or lacks growth-promoting molecules.

144 upling protein-2 (UCP-2) or (2) induction of growth inhibitor p21 leading to G1/S phase arrest was te

145 e whether the interactions between the human growth inhibitor p21WAF1 and PCNA from plants and humans

146 ion and stability of the ovarian cancer cell growth inhibitor peptide, LSCQLYQR (LR), is vital for le

147 y the target of a Mycobacterium tuberculosis growth inhibitor, pointed to a mechanism involving a sca

148 inase (MAPK) by endogenous growth factors or growth inhibitors provides a potential means of regulati

149 nophilin and small Ras family G protein cell growth inhibitor RASD1 genes.

150 A mammary-derived growth inhibitor-related gene (MRG) was previously ident

151 mmary gland and named it the mammary-derived growth inhibitor-related gene (MRG).

152 inhibitor and thus was named mammary-derived growth inhibitor-related gene (MRG).

153 Profiling of eight stereoisomeric T. cruzi growth inhibitors revealed vastly different in vitro pro

154 e of Rtn4b, the homologue of the rat neurite growth inhibitor RTN4-A/Nogo-A.

155 Here, we characterize a small, heat-stable growth inhibitor secreted by a rat T lymphoma line when

156 ulates RNA interference (RNAi) and acts as a growth inhibitor selectively in cancer but not in untran

157 central nervous system scar associated axon growth inhibitors, semaphorin 3A has been shown to be st

158 APF is therefore a frizzled-related peptide growth inhibitor shown to contain exclusively a transmem

159 non-permissive environment, including axonal growth inhibitors such as the Nogo-A protein.

160 It has been suggested that axon growth inhibitors, such as myelin-derived Nogo, prevent

161 enzymes, the LOX inhibitors were more potent growth inhibitors than the COX inhibitors.

162 results suggest that the prodrug is a potent growth inhibitor that can bypass dCK deficiency at highe

163 Thus, we have identified a novel growth inhibitor that is down-regulated by estrogens and

164 Pladienolide B (PB) is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the s

165 teoglycans (CSPGs) are a major class of axon growth inhibitors that are up-regulated after spinal cor

166 be hypothetical circulating, tissue-specific growth inhibitors that control tissue size.

167 We also suggest that existence of growth inhibitors that counteract the action of Wingless

168 and synthetic modifiers tend to function as growth inhibitors that hinder solute attachment and impe

169 One hypothesis is that the nerve contains growth inhibitors that must be neutralized after injury

170 nique among antimalarials and common crystal growth inhibitors, that opens new avenues for evaluating

171 d that OKL38/OSGN1 (oxidative stress-induced growth inhibitor), the hub gene in the blue module, is a

172 erate is the presence of myelin-derived axon growth inhibitors, the role of which, however, remains p

173 The INK4a gene encodes two distinct growth inhibitors--the cyclin-dependent kinase inhibitor

174 operation and convert TGF-beta from a potent growth inhibitor to a tumor promoter are not fully under

175 We introduce the use of a growth inhibitor to enhance thin film conformality in lo

176 s a newly described membrane-bound astrocyte growth inhibitor to limit neuroplasticity, activity-depe

177 d stg, in combination with repression of the growth inhibitor tok.

178 Psi directly represses transcription of the growth inhibitor tolkin (tok, a metallopeptidase implica

179 he mitogen IGF-II, promote activation of the growth inhibitor transforming growth factor beta, and re

180 survivin and Bcl-2 and downregulation of the growth inhibitor transforming growth factor-beta and pro

181 xpressed the oncogenes H-ras and raf and the growth inhibitor transforming growth factor-beta1.

182 nalyze the pathways that these two different growth inhibitors use for antagonizing breast cancer cel

183 Vascular endothelial cell growth inhibitor (VEGI), a member of the tumor necrosis

184 Vascular endothelial growth inhibitor (VEGI), a new member of the tumor necro

185 ell cDNA library, named vascular endothelial growth inhibitor (VEGI).

186 y, we report that human vascular endothelial growth inhibitor (VEGI, TNF superfamily 15), an endothel

187 Vascular endothelial growth inhibitor (VEGI; TNFSF15) has been shown to inhib

188 A novel human tumor growth inhibitor was identified by differential cDNA seq

189 Induction of most growth inhibitors was delayed but not abolished in cells

190 ion of growth cone responses to various axon growth inhibitors, we asked whether raising cAMP levels

191 The identities of the three EC growth inhibitors were confirmed by demonstrating that r

192 gram of cell cycle control in which numerous growth inhibitors were upregulated and mitogenic genes w

193 The most potent growth inhibitors where N-[methyl(4-phenylalkyl)]-3-amin

194 med RERG (ras-related and estrogen-regulated growth inhibitor), whose expression was decreased or los

195 The data show a novel class of growth inhibitors with a wide spectrum of action that in

196 ss of tubulin polymerization and cancer cell growth inhibitors with the potential to inhibit the Hedg

197 e of these, OSM, is among the most potent EC growth inhibitors yet reported.